Abbott’s new system helps surgeons identify and treat the areas where arrhythmias originate. Credit: DennisM2 / Flickr.

The US Food and Drug Administration (FDA) has granted clearance to Abbott’s new cardiac mapping platform, EnSite X EP System with EnSite Omnipolar Technology (OT), which is designed to help physicians treat cardiac arrhythmias.

Available in the US and across Europe, the system is designed to create detailed 3D maps of the heart that allow surgeons to identify and treat areas where arrhythmias originate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The device includes the company’s EnSite OT, which uses the Advisor HD Grid Catheter to provide true electrograms (EGMs) regardless of catheter orientation in the heart.

The EnSite X EP System with EnSite OT has the ability to provide a 360° view of the heart for cardiac mapping.

This allows the system to map one million points in the heart, which helps to identify the precise locations of areas that require treatment.

Abbott electrophysiology senior vice-president Mike Pederson said: “As ablation therapy is increasingly used for patients battling cardiac arrhythmias, new, innovative and advanced cardiac mapping and imaging tools are essential to help physicians provide the best outcomes for their patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We developed the EnSite X System with EnSite OT to enhance the utility of our unique Advisor HD Grid catheter and allow doctors to quickly and accurately create real-time, stable, three-dimensional models of the heart.

“These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue.”

The company stated that the EnSite X EP System with EnSite OT offers the best of unipolar and bipolar measurement principles to provide cardiac mapping without compromise.

Furthermore, the device is claimed to be the first mapping system that allows doctors to use both cardiac visualisation methods.

Last November, Abbott submitted positive data from the Leadless II IDE trial, which evaluated its Aveir leadless pacemaker in patients with certain types of abnormal rhythms, to the FDA.